Related ArticlesDrug evaluation: the C5a receptor antagonist PMX-53.
Curr Opin Mol Ther. 2006 Dec;8(6):529-38
Authors: Köhl J
Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.
PMID: 17243489 [PubMed - in process]
]]>
Related ArticlesInfliximab (Remicade) in the treatment of psoriatic arthritis.
Ther Clin Risk Manag. 2006 Dec;2(4):389-400
Authors: Mease P
Elucidation of the cellular immunopathology and cytokine profile of psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, has resulted in the development of a number of novel biologic therapies. Among these biologics, tumor necrosis factor-alpha (TNF-alpha) inhibitors have been used successfully to treat patients suffering from rheumatoid arthritis or psoriasis. The pivotal role of TNF-alpha in the pathogenesis and progression of PsA suggested that anti-TNF-alpha agents could be effective in controlling PsA. The results from two large, randomized, double-blind, placebo-controlled trials in patients with moderate to severe PsA indicated that the anti-TNF-inhibitor, infliximab, can control both the joint and skin manifestations of the disease. This review focuses on the clinical development of infliximab as a treatment for PsA. The development of other anti-TNF-alpha biologics is also discussed.
PMID: 18360651 [PubMed - in process]
]]>